Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 410

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 410
---
 |   |
| Issuance of Series A shares sold to investors, net                                 |     |                 |  7,854 |     |        | 6,755,698 |     |              |     - |   |     |        | - |     |            |   (856,663 | ) |     |              | -          |   |     |             | -           |   |     |       |   5,899,035 |   |
| Issuance of Series A Preferred Warrants                                            |     |                 |      - |     |        |         - |     |              |     - |   |     |        | - |     |            |  2,000,000 |   |     |              | (2,000,000 | ) |     |             | -           |   |     |       |           - |   |
| Issuance of common shares to Keystone Capital LLC for equity line of credit        |     |                 |      - |     |        |         - |     |              |    59 |   |     |        | - |     |            |    633,345 |   |     |              | -          |   |     |             | -           |   |     |       |     633,345 |   |
| Opening Equity at February 14, 2024 (Successor)                                    |     |                 | 10,089 |     | $      | 8,937,852 |     |              | 7,266 |   |     | $      | 1 |     | $          | 53,899,885 |   |     | $            | (2,000,000 | ) |     | $           | (63,185,641 | ) |     | $     |  (2,347,903 | ) |

F-48

NOTE 4 – NET LOSS PER SHARE OF COMMON STOCK

The accounting standards
require the presentation of both basic and diluted earnings per share on the face of the statements of operations. The Company’s
basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the
period. If there are dilutive securities, diluted income per share is computed by including common stock equivalents which includes shares
issuable upon the exercise of stock options into shares of common stock, exercise of preferred warrants into shares of preferred stock,
and conversion of preferred stock into shares